摘要
目的:分析木丹颗粒联合尼莫地平治疗糖尿病周围神经病变的效果。方法:选用回顾性的研究方式,收集符合标准的糖尿病周围神经病变患者115例临床资料,其中接受尼莫地平治疗的57例作对照组,接受木丹颗粒联合尼莫地平治疗的58例作研究组,均持续治疗3个月,统计2组疗效、中医证候积分、多伦多临床神经病变评分系统(TCSS)、血清神经标志物[脑源性神经营养因子(BDNF)、磷髓脂碱性蛋白(MBP)、神经生长因子(NGF)]水平、神经传导速度[运动神经传导速度(MNCV)感觉神经传导速度(SNCV)]、不良反应。结果:较对照组70.18%,研究组治疗效果89.66%偏高(P<0.05);治疗后,研究组中医证候积分与TCSS分值比对照组低(P<0.05);研究组治疗后正中神经SNCV和MNCV、腓总神经SNCV和MNCV比对照组高(P<0.05);治疗后研究组NGF、BDNF比对照组高,MBP比对照组低(P<0.05);2组不良反应比较,无明显差异(P>0.05)。结论:木丹颗粒联合尼莫地平治疗糖尿病周围神经病变效果显著,可减轻病情程度,增加神经传导速度,改善神经标志物水平,且未增加明显不良反应。
Objective:To analyze the efficacy of Mudan granules combined with nimodipine in the treatment of dia-betic peripheral neuropathy.Methods:A retrospective study was conducted to collect clinical data from 115 patients with diabetic peripheral neuropathy who met the criteria.Fifty-seven patients received nimodipine as the control group,and 58 patients received Mudan granules combined with nimodipine as the study group.Treatment lasted for 3 months.The efficacy,TCM syndrome scores,Toronto Clinical Neuropathy Scoring System(TCSS),serum neuromarker levels[brain-derived neurotrophic factor(BDNF),myelin basic protein(MBP),nerve growth factor(NGF)],nerve conduction velocity motor nerve conduction velocity(MNCV)and sensory nerve conduction velocity(SNCV),and adverse reactions were statistically analyzed between the two groups.Results:The treatment efficacy in the study group was 89.66%,significantly higher than the control group’s 70.18%(P<0.05).After treatment,the TCM syndrome score and TCSS score in the study group were lower than those in the control group(P<0.05).After treatment,the median nerve SNCV and MNCV,as well as the common peroneal nerve SNCV and MNCV,were higher in the study group than in the control group(P<0.05).After treatment,NGF and BDNF levels were higher,and MBP was lower in the study group than in the control group(P<0.05).No significant difference was found in adverse reactions between the two groups(P>0.05).Conclusion:Mudan Granule combined with nimodipine is effective in treating diabetic peripheral neuropathy,alleviating disease severity,increasing nerve conduction velocity,and improving neuromarker levels without significantly increasing adverse reactions.
作者
张晶晶
史晓阳
李丹丹
ZHANG Jingjing;SHI Xiaoyang;LI Dandan(The Third People’s Hospital of Kaifeng,He’nan Kaifeng 475000,China;He’nan Provincial People’s Hospital,He’nan Zhengzhou 450000,China;Huaihe Hospital of Henan University,He’nan Kaifeng 475000,China)
出处
《中医药临床杂志》
2025年第9期1812-1816,共5页
Clinical Journal of Traditional Chinese Medicine
基金
河南省医学科技攻关联合共建项目(LHGJ20228347)。
